A dipeptide of two of the most common amino acids in biology—claimed to restore bladder function, studied in one uncontrolled group of 20 women, with no independent verification.

Vesilute occupies the thinnest edge of the Khavinson bioregulator family. It is the simplest molecule—a dipeptide of just two amino acids, glutamic acid and aspartic acid. Its molecular weight is approximately 262 daltons, making it the smallest bioactive peptide in Peptidings Cluster S. For comparison, Vilon (Lys-Glu) weighs ~275 Da. Vesilute is one of the two smallest peptides ever investigated for biological activity.

The compound is described as targeting the bladder and urogenital system, addressing overactive bladder (OAB) and incontinence. The evidence for this claim rests on a single source: a 20-woman observational study cited by vendor websites but not independently verified on PubMed. No controlled trial has been published. No preclinical animal studies (lifespan, tumor, pharmacokinetic) have been indexed in English. The compound appears to exist primarily in the commercial peptide market with no published research pathway behind it.

Vesilute closes the Khavinson Evidence Problem discussion that runs through all nine compounds in Cluster S. But it poses the problem in its sharpest form: two of the most abundant amino acids in biology—glutamic acid and aspartic acid—are proposed to achieve organ-specific effects. These amino acids are the building blocks of virtually every protein in the human body. How does a free dipeptide of these two sequences, administered at microgram doses, produce selective effects on bladder tissue while sparing identical amino acid sequences in liver, heart, kidney, and immune cells? This is not a scientific objection—it is a mechanistic and specificity question that becomes most pressing where the evidence is thinnest.

Quick Facts: Vesilute at a Glance

What Is Vesilute?

Pronunciation: VES-ih-loot

Vesilute is a synthetic dipeptide—a molecule made of exactly two amino acids, L-glutamic acid and L-aspartic acid, joined by a single peptide bond. Its molecular weight is approximately 262 daltons, making it one of the smallest peptides studied for any biological activity.

It belongs to the family of Khavinson bioregulators—ultrashort peptides (2–7 amino acids) developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. The bioregulator paradigm proposes that these ultrashort peptides are not traditional receptor agonists. They do not work through G-protein-coupled receptors, ion channels, or cytokine receptors in the manner of most Western-developed peptide drugs. Instead, they are proposed to enter cells, cross nuclear membranes, interact directly with DNA and histone proteins, and modulate gene expression in an organ-specific manner.

Vesilute's target, according to its developers, is the bladder and urogenital system. It is claimed to address overactive bladder (OAB) syndrome and related incontinence conditions.

The Specificity Question—Vesilute's Central Problem

This is the most critical section of this brief. It describes the core mechanistic challenge that applies to all Khavinson bioregulators but becomes most acute for Vesilute.

Two Amino Acids Among Thousands of Proteins

Glutamic acid and aspartic acid are the two most abundant acidic amino acids in human biology. Every human protein is built from a repertoire of 20 amino acids. Glutamic acid (E) and aspartic acid (D) together comprise 15–20% of the amino acid content of most proteins. A free dipeptide of glutamic acid and aspartic acid—the sequence "ED"—appears as a subsequence within thousands of different proteins throughout the human body.

Examples: - Insulin contains a Glu-Asp sequence in its receptor-binding domain - Collagen (in bladder smooth muscle and connective tissue) contains extensive Glu-Asp stretches - Actin and myosin (bladder smooth muscle contractile proteins) both contain this sequence - Gap junction proteins (connexins, involved in bladder muscle coordination) contain Glu-Asp motifs - Glutamate and aspartate receptors throughout the nervous system share this amino acid pair as their principal ligands

The Dosing Paradox

A microgram-quantity injection of a free Vesilute dipeptide is proposed to produce selective effects on bladder tissue while leaving identical amino acid sequences in cardiac muscle, vascular smooth muscle, skeletal muscle, liver, kidney, and the central nervous system completely unaffected.

Every meal delivers gram-quantities of glutamic acid and aspartic acid to the bloodstream as dietary protein breaks down. Vegetable broth alone contains milligram quantities of free glutamic acid (monosodium glutamate). The bioregulator claim is that a microgram dipeptide produces specific effects that dietary protein does not. The fact that glutamic acid and aspartic acid are the principal excitatory and inhibitory neurotransmitters in the central nervous system—and that the proposed bioregulator targets them—raises questions about why systemic effects are not observed.

The Mechanism — Unstated Questions

The Khavinson paradigm proposes that Vesilute, like all bioregulators, achieves organ specificity through:

1. Tissue-preferential uptake — ? (no transport mechanism demonstrated) 2. Cell membrane permeability — probably high for a dipeptide, but not measured for Vesilute 3. Nuclear envelope crossing — ? (proposed but not demonstrated in vivo) 4. DNA sequence selectivity — computational predictions exist for Khavinson's broader dipeptide library, but none have been published specifically for the ED sequence in bladder-specific genes 5. Metabolic resistance to peptidases — dipeptides are typically degraded within seconds to minutes by ubiquitous dipeptidyl peptidases; unknown for Vesilute in vivo

No independent lab has tested any of these hypotheses for any Khavinson bioregulator. No Western pharmacology framework addresses how a dipeptide achieves organ-specific nuclear targeting.

Origins and Development

The history of Vesilute is less clear than that of other Cluster S compounds. Vilon and Thymogen have publication records. Vesilute does not.

The compound is described as part of the broader Khavinson bioregulator research program, initiated in 1973 within the Soviet military medical system. The program's original focus was immune system restoration (Thymalin) and endocrine regulation (Epithalamin). Over decades, the program expanded to other organs—thymus (Vilon, Thymogen), pancreas (Pancragen), blood vessels (Vesugen), liver (Livagen, Ovagen), prostate (Prostamax), testes (Testagen), and bladder (Vesilute).

The bladder peptide (Vesilute) appears to be a product of this systematic organ-targeting approach—select an organ of interest, extract and fractionate peptides from that tissue, test the fractions in animal or cell-culture models, synthesize the candidate peptide, then move to human testing or commercialization. For Vilon and Thymogen, this pathway was transparent through publications. For Vesilute, it was not.

Lack of Publication Record

No peer-reviewed studies on Vesilute appear in PubMed-indexed literature in English. No Russian-language publication record (accessible to Peptidings) has been located. The compound appears primarily through vendor websites and supplement marketing materials—typically listed among "Khavinson bioregulators" with a brief mention of the 20-woman bladder study.

This absence of publication record distinguishes Vesilute from even the thinnest-evidence compounds in the cluster. Ovagen, Prostamax, and Testagen have at least been mentioned in Khavinson publications. Vesilute has not.

Mechanism of Action

The proposed mechanism for Vesilute follows the standard Khavinson bioregulation framework.

The Bioregulation Hypothesis Applied to Bladder

According to the bioregulator paradigm, Vesilute enters bladder smooth muscle cells and enters cell nuclei due to its extremely small size (~262 Da). Once inside the nucleus, it is proposed to:

1. Interact with DNA — specifically with promoter regions of genes involved in bladder smooth muscle function, including genes controlling muscle tone, sensory innervation, and gap junction formation 2. Bind histone proteins — modifying chromatin structure 3. Decondense heterochromatin — converting tightly packed, transcriptionally silent DNA back into open, active DNA 4. Reactivate age-silenced genes — restoring expression of genes involved in normal bladder function that become progressively silenced with aging

This process is proposed to restore bladder capacity, muscle tone, and sensory control—addressing the symptoms of overactive bladder.

No Direct Evidence

No published study demonstrates that Vesilute achieves any of these steps in a living bladder. No animal models testing Vesilute on bladder function have been published. No human pharmacokinetic studies establishing that the compound reaches bladder tissue, crosses cell membranes, or enters nuclei have been reported.

Key Research Areas and Studies

This is the briefest section in any Cluster S brief because Vesilute has generated virtually no peer-reviewed research.

The 20-Woman Observational Study (Unverified)

Source: Vendor websites citing an unspecified study.

According to commercial peptide suppliers, Vesilute was tested in a group of 20 women with overactive bladder syndrome (OAB). Reported outcomes: - Maximum cystometric capacity (bladder volume at first contraction): 267 mL → 320 mL - Daytime urination frequency: 14 episodes → 11 episodes - Nocturia (nighttime episodes): 4 → 2

These are clinically meaningful improvements if real. The cystometric capacity increase (53 mL) is substantial. The reduction in frequency and nocturia would significantly improve quality of life.

However: - This study is not indexed on PubMed - The original study design, sample characteristics, control group (if any), blinding status, and statistical analysis are not described - The study is cited by vendor sources only—not by independent researchers - No citation or reference is provided that would allow verification - No replication or follow-up study has been published

This single uncontrolled observation is the entirety of the human evidence for Vesilute.

Absence of Preclinical Work

No animal studies (mouse, rat, guinea pig) testing Vesilute on bladder function have been published in PubMed-indexed English-language literature. No rodent OAB models have been run with this compound. No dose-ranging studies. No pharmacokinetic studies (absorption, distribution, half-life, elimination).

Chromatin Studies (General Bioregulator Paradigm)

As with other Khavinson bioregulators, Vesilute is proposed to work through the same chromatin decondensation mechanism documented for Vilon, Thymogen, and Livagen. But no specific chromatin studies with Vesilute have been published.

The Khavinson Evidence Problem

The Khavinson Evidence Problem applies to Vesilute with a critical intensification: Vesilute has less evidence than any other compound in the cluster.

Single-Lab Dependency — Zero Replication

All other Cluster S compounds have at least some publication record from Khavinson's lab. Vilon has mouse lifespan data and multiple in vitro studies. Thymogen has a rat lifespan study published in Biogerontology. Livagen has human ex vivo chromatin data. Even Testagen, Prostamax, and Ovagen (the thinnest in the cluster) have chromatin or animal model data in Russian literature.

Vesilute has no published studies—not in Khavinson's literature, not in Georgian collaborator literature, not in Russian-language journals on PubMed. The compound exists only in vendor marketing.

This is not "single-source" evidence. This is no published evidence at all.

The Unverified Human Study

The 20-woman observational study is cited exclusively by vendors. It has not been published in a peer-reviewed journal. No citation exists that would allow a researcher to retrieve the original data. The study design, inclusion/exclusion criteria, outcome measures, blinding, and statistical methods are not specified anywhere in accessible literature.

An uncontrolled observational study of 20 subjects would normally be considered Case Series evidence—weak but acceptable as hypothesis-generating data. But when the study itself is not publicly accessible, not peer-reviewed, and available only through promotional materials, it cannot be evaluated at all.

The Absence of Any Western Regulatory Engagement

Vesilute has never been submitted to the FDA, EMA, or any Western regulatory agency. It has no ClinicalTrials.gov registration. There is no indication that the compound has been the subject of any pharmacokinetic study, toxicology assessment, or GCP-compliant human trial.

The Specificity Question at Its Sharpest

For Vilon (Lys-Glu), the specificity question is: how do two common amino acids achieve thymic selectivity? The answer might exist in the literature—differential DNA sequence selectivity, differential peptidase stability in thymic tissue, or differential cell membrane transporters in thymic cells.

For Vesilute (Glu-Asp), the specificity question is even more acute. Glutamic acid and aspartic acid are the most abundant acidic amino acids in human biology. They are not tissue-specific. They appear in thousands of proteins. The excitatory and inhibitory neurotransmitter systems of the central nervous system are built on glutamate and aspartate signaling. How does a dipeptide of these two amino acids produce selective bladder effects without affecting the nervous system, cardiovascular system, or kidneys?

The Khavinson literature proposes computational DNA-binding models that might explain selectivity. But these have not been validated experimentally for any bioregulator, and certainly not for Vesilute.

Claims vs. Evidence

The Human Evidence Landscape

There is no controlled human evidence for Vesilute. There is no uncontrolled human evidence published in a peer-reviewed journal.

The closest to human data is the vendor-cited 20-woman observational study—which is not publicly accessible, not peer-reviewed, and cannot be independently audited.

What Would Constitute Credible Human Evidence

For Vesilute to meet any standard of human evidence, the following would be necessary:

1. Publication of the original 20-woman study in a peer-reviewed journal (even a low-tier journal) with full methods, inclusion/exclusion criteria, outcome definitions, and statistical analysis 2. Replication of the finding in an independent group of OAB subjects 3. A placebo-controlled trial in a defined OAB population with standard outcome measures (International Continence Society validated scales) 4. A dose-ranging study establishing tolerable and biologically active doses in humans

The Silence Around Vesilute

The absence of any publication is itself noteworthy. If Vesilute produced the improvements reported in the 20-woman study (53 mL capacity increase, 3-episode reduction in daytime frequency, 2-episode reduction in nocturia), this would be a publishable finding. OAB is a high-burden condition affecting hundreds of millions of people globally. A safe, novel treatment would have significant clinical and commercial interest.

The fact that no publication has emerged suggests either: (a) the study does not exist or does not show what vendors claim, or (b) the study exists but the compound's developers chose not to publish it. Both possibilities undermine confidence.

Safety, Risks, and Limitations

No Formal Safety Data

No toxicology studies, pharmacokinetic studies, or human safety assessments exist for Vesilute in any accessible literature.

Theoretical Safety Advantage

As a dipeptide of two common amino acids, Vesilute has a favorable theoretical safety profile. Rapid enzymatic degradation by ubiquitous dipeptidyl peptidases is expected. The molecule is unlikely to accumulate, cause immune reactions, or produce off-target receptor effects.

This theoretical safety argument is plausible but not validated by formal toxicology, pharmacokinetics, or GCP-compliant human trials.

Unknown Pharmacokinetics

The absorption, distribution, metabolism, and excretion (ADME) of Vesilute in humans is completely unknown. Does the dipeptide survive the bloodstream long enough to reach bladder tissue? If it does reach the bladder, does it penetrate smooth muscle cell membranes? If it enters cells, does it cross the nuclear membrane? How much reaches intact in the nucleus versus being degraded by intracellular peptidases?

These are not rhetorical questions. They are fundamental pharmacological questions that must be answered before any therapeutic claim can be made. For Vesilute, they have not been addressed.

The Dietary Amino Acid Comparison

Glutamic acid and aspartic acid are consumed at gram quantities in everyday food. Vegetable proteins are rich in glutamic acid. Dairy products contain aspartic acid. The human body synthesizes these amino acids endogenously from carbohydrate and protein metabolism.

The claim that a microgram-dose dipeptide of these amino acids produces selective biological effects raises questions that the absence of any pharmacological evidence leaves unresolved. Why would a dietary change not produce the same effects? How is specificity achieved in the face of continuous dietary exposure to the same building blocks?

Legal and Regulatory Status

FDA Status

Vesilute has never been approved, reviewed, or submitted to the FDA. It is not an authorized pharmaceutical ingredient in the United States.

Russian Status

Vesilute is not a registered pharmaceutical in Russia. Unlike related compounds (Thymalin is registered; Thymogen is registered), no pharmaceutical approval has been granted for this compound in any country.

WADA Status

Vesilute is not specifically listed on the WADA prohibited list. As a synthetic dipeptide, it may fall under S2 (Peptide hormones, growth factors, and related substances) depending on classification—but this is ambiguous for a two-amino-acid molecule with no established hormonal activity.

Market Availability

Vesilute is available through research peptide suppliers, typically as lyophilized powder labeled "for research purposes only." Purity, identity, and sterility are not regulated by any Western agency.

Research Protocols and Formulation Considerations

Chemical Composition

Vesilute is a synthetic dipeptide: L-Glutamyl-L-Aspartic acid. Molecular weight: ~262 Da. Molecular formula: C₇H₁₀N₂O₆.

Synthesis

Synthesized via standard solid-phase or solution-phase peptide synthesis. The molecule is small enough that synthesis is trivial by modern peptide chemistry standards.

Stability

As a dipeptide, Vesilute is susceptible to rapid degradation by ubiquitous aminopeptidases and dipeptidyl peptidases present throughout biological fluids. Stability in solution is limited. Lyophilized powder is the standard storage form.

Formulation

Research-grade Vesilute is typically supplied as lyophilized powder, reconstituted with bacteriostatic water or saline. Some vendors offer capsule formulations intended for oral or sublingual administration.

Dosing in Published Research

Route of Administration

No published study specifies the route of administration for Vesilute in humans or animals. Vendor protocols suggest subcutaneous injection or sublingual administration, but these are extrapolations from other Khavinson bioregulators, not evidence-based for this compound.

Doses in Published Studies

No published dosing data exists for Vesilute.

Pharmacokinetics

Unknown in humans and animals. The half-life of a free dipeptide in human plasma is expected to be very short (minutes) due to rapid enzymatic degradation by dipeptidyl peptidases.

Dosing in Self-Experimentation Communities

WHY NEARLY EMPTY: Vesilute has minimal community adoption even within the niche Khavinson bioregulator market. The bladder-specific indication is more limited in appeal than thymic immunity (Vilon, Thymogen) or broader longevity claims. Community dosing protocols are virtually nonexistent.

Reported Community Doses

Vendor websites suggest doses in the range of 100–200 mcg/day subcutaneously or sublingually. These doses are not derived from any published study. They appear to be extrapolated from Russian supplement protocols and vendor marketing materials, with no pharmacological or safety basis.

Combination Stacks

Research into Vesilute combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.

If you are considering combining Vesilute with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.

Frequently Asked Questions

Summary of Key Findings

Vesilute is the final compound in Cluster S—and its evidence base, or more accurately the absence of one, closes the cluster's central editorial narrative.

It is the smallest molecule in the family (262 Da), a simple dipeptide of two amino acids that comprise the foundation of nearly every protein in human biology. It is claimed to address overactive bladder based on a single observational study of 20 women that is not published in peer-reviewed literature, not indexed on PubMed, and available only through vendor marketing materials.

Unlike Vilon (which has mouse lifespan data, tumor inhibition studies, and in vitro chromatin evidence), unlike Thymogen (which has a rat lifespan study and Russian pharmaceutical registration), and unlike even the thinnest-evidence compounds like Testagen or Prostamax (which at least have chromatin studies or animal models published in Russian literature)—Vesilute has generated zero peer-reviewed research. No publications. No animal studies. No human trials. No pharmacokinetic data.

This is not evidence of absence. This is absence of evidence. And for a compound positioned to treat a condition affecting millions of people globally, the absence is conspicuous.

The specificity question—how a dipeptide of two ubiquitous amino acids achieves organ-specific effects—becomes most pressing here, where the evidence is thinnest. The claim requires an extraordinary level of molecular specificity: tissue-preferential uptake, cell membrane crossing, nuclear envelope penetration, and DNA binding to bladder-specific promoters. None of this has been demonstrated.

Verdict Recapitulation

Vesilute earns "Thin Ice" because it represents the endpoint where the Khavinson paradigm meets the limits of credible evidence. The absence of any peer-reviewed publications, the unverifiability of the single human observation, the complete lack of preclinical work, and the mechanistic implausibility of organ-specific effects from a ubiquitous amino acid dipeptide—all combine to create the thinnest evidence case in Cluster S. This is not a condemnation of the Khavinson framework itself (Vilon, Thymogen, and Livagen represent more substantive evidence packages for that paradigm). This is a recognition that Vesilute exists at the market frontier where commercial product precedes any published evidence. It is the compound where a reader must most clearly see the gap between vendor claims and scientific validation.

For readers considering Vesilute, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.

Where to Source Vesilute

Further Reading and Resources

If you want to go deeper on Vesilute, the evidence landscape for khavinson bioregulators peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

ON PEPTIDINGS

• Khavinson Bioregulators Research Hub — Overview of all compounds in this cluster
• Reconstitution Guide — How to properly prepare injectable peptides
• Storage and Handling Guide — Proper storage to maintain peptide stability
• About Peptidings — Our editorial methodology and evidence framework

EXTERNAL RESOURCES

• PubMed: Vesilute — All indexed publications
• ClinicalTrials.gov — Active and completed trials

Selected References and Key Studies

1. Khavinson VKh, Kuznik BI, Ryzhak GA. "Peptide bioregulators: the new class of geroprotectors. Communication 1. Results of experimental studies." Advances in Gerontology. 2012;25(4):696–708. PMID 23734519 (Cluster-wide reference)
2. Khavinson VKh, Kuznik BI, Ryzhak GA. "Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results." Advances in Gerontology. 2013;26(1):20–37. PMID 24003726 (Cluster-wide reference — lists Vesilute briefly among compounds studied)
3. Deigin VI et al. "Development of peptide biopharmaceuticals in Russia." Pharmaceutics. 2022;14(4):716. PMC: 9030433

---